ICD Promotion For New Indications May Not Need PMA Supplements - FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA would still need to consider on a case-by-case basis whether a premarket approval application supplement would be required for manufacturers to promote new indications for implantable cardioverter defibrillators (ICDs) under the agency's proposed labeling change for the devices.